Publications, Pharmaceutical

Nasal Drug Development, Trends and Challenges with Nasal Formulations

The confluence of COVID-19, growing recognition of the potential for nose-to-brain drug delivery and the recent success of rapid rescue remedies makes it an exciting time to be working in nasal drug delivery.

This Q&A considers the critical factors that influence nasal drug product development and current trends in formulation practice and science.

The need for a better understanding of precisely where to target nasal drug delivery, and how, is highlighted, along with requirements for better models of mucociliary clearance to tackle the challenge of improving retention. Going forward it is anticipated that nasal drug delivery will be used more, and for a wider range of drugs, notably vaccines and other biologics including mRNA and antibodies.

Download the Nasal Drug Delivery Q&A
Author(s): Dr Irene Rossi
25 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out MORE ABOUT NASAL DRUG DELIVERY EXPERTISE

This Might Also Be of Interest

18 Sep 2018

Aptar Pharma provides guidance on FDA regulatory framework for OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 Jun 2018

Connected Medicine: Insights from Payers and Other Stakeholders

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
1 Apr 2018

A track record of success for nasal drug delivery in drug repurposing

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
16 Sep 2016

The Nasal Drug Delivery Journey: from Systemic to Nose-to-Brain?

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 24 25 26 27

Request Access

Close

Requesting access to Nasal Drug Development, Trends and Challenges with Nasal Formulations.

  • This field is for validation purposes and should be left unchanged.
Back To Top